Gelonghui, June 13丨The Dongwu Securities Research Report points out that the century-old heritage is rich, and the implementation of the Da Rentang (600329.SH) mixed reform has begun a new journey. The company's “three cores and nine wings” strategy continues to advance. Individual products from various production lines, such as quick-acting heart saving pills, throat cleansing pills, and Jingwanhong Ointment, are expected to blossom more in the context of marketing reforms, helping the company achieve the “14th Five-Year Plan” industrial sector revenue growth of 18% per year. The company's organizational management optimization, marketing strategy reform, and industrial chain restructuring help new growth in performance. The bank takes into account the company's century-old heritage and rich heritage. In the context of mixed reform and implementation and marketing reform, the company's “three cores and nine wings” strategy continues to advance, and various product lines are expected to blossom more. It expects the company's net profit of 2023-2025E to be 1,114/1,390/1,738 million yuan respectively, corresponding to the current stock price PE 33/26/21 times, respectively. First coverage, giving a “buy” rating.